BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22553052)

  • 1. Novel small molecule Raf kinase inhibitors for targeted cancer therapeutics.
    Kim DH; Sim T
    Arch Pharm Res; 2012 Mar; 35(4):605-15. PubMed ID: 22553052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.
    McCubrey JA; Milella M; Tafuri A; Martelli AM; Lunghi P; Bonati A; Cervello M; Lee JT; Steelman LS
    Curr Opin Investig Drugs; 2008 Jun; 9(6):614-30. PubMed ID: 18516761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
    Gollob JA; Wilhelm S; Carter C; Kelley SL
    Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raf kinase inhibitors in oncology.
    Strumberg D; Seeber S
    Onkologie; 2005 Feb; 28(2):101-7. PubMed ID: 15665559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.
    Friday BB; Adjei AA
    Clin Cancer Res; 2008 Jan; 14(2):342-6. PubMed ID: 18223206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B-Raf kinase inhibitors for cancer treatment.
    Li N; Batt D; Warmuth M
    Curr Opin Investig Drugs; 2007 Jun; 8(6):452-6. PubMed ID: 17621874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
    Roberts PJ; Der CJ
    Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic strategies for inhibiting oncogenic BRAF signaling.
    Halilovic E; Solit DB
    Curr Opin Pharmacol; 2008 Aug; 8(4):419-26. PubMed ID: 18644254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is B-Raf a good therapeutic target for melanoma and other malignancies?
    Madhunapantula SV; Robertson GP
    Cancer Res; 2008 Jan; 68(1):5-8. PubMed ID: 18172288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raf: a strategic target for therapeutic development against cancer.
    Beeram M; Patnaik A; Rowinsky EK
    J Clin Oncol; 2005 Sep; 23(27):6771-90. PubMed ID: 16170185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raf pathway inhibitors in oncology.
    Bollag G; Freeman S; Lyons JF; Post LE
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1436-41. PubMed ID: 14763129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors.
    Xia Y; Choi HK; Lee K
    Eur J Med Chem; 2012 Mar; 49():24-40. PubMed ID: 22305612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small-molecule PARP modulators--current status and future therapeutic potential.
    Penning TD
    Curr Opin Drug Discov Devel; 2010 Sep; 13(5):577-86. PubMed ID: 20812149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II RAF kinase inhibitors in cancer therapy.
    Turajlic S; Ali Z; Yousaf N; Larkin J
    Expert Opin Investig Drugs; 2013 Jun; 22(6):739-49. PubMed ID: 23642225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raf kinases: oncogenesis and drug discovery.
    Schreck R; Rapp UR
    Int J Cancer; 2006 Nov; 119(10):2261-71. PubMed ID: 16894562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the ERK signaling pathway in cancer therapy.
    Kohno M; Pouyssegur J
    Ann Med; 2006; 38(3):200-11. PubMed ID: 16720434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the RAF-MEK-ERK pathway in cancer therapy.
    Montagut C; Settleman J
    Cancer Lett; 2009 Oct; 283(2):125-34. PubMed ID: 19217204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway.
    Maira SM; Furet P; Stauffer F
    Future Med Chem; 2009 Apr; 1(1):137-55. PubMed ID: 21426073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in the research and development of RAF kinase inhibitors.
    Smith RA; Dumas J; Adnane L; Wilhelm SM
    Curr Top Med Chem; 2006; 6(11):1071-89. PubMed ID: 16842147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.